Nat. Rev. Rheumatol. doi: /nrrheum

Slides:

Advertisements

Similar presentations

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Advertisements

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Immune Receptors and Signal Transduction

Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll Cancer Cell

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Radiation-induced effects on tumour cells

Figure 2 Immune-escape mechanisms of CTCs in the peripheral blood

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Induction of immune tolerance

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Figure 3 Altered adaptive immune functions after sepsis

Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 1 Four nodes to target when inducing anti-tumour immunity

Figure 1 Postulated mechanisms of action of PD‑1, PD‑L1 and PD‑L2

Figure 1 Chimeric antigen receptor (CAR) structures

Figure 2 Peptide vaccination using TAA-derived long peptides

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

Figure 7 Clinical options for HCC therapy

Oncology Meets Immunology: The Cancer-Immunity Cycle

Figure 1 Immune mechanisms in liver homeostasis

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Classification of immunotherapies

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 7 Defects in apoptosis

Figure 1 CAR-T-cell design

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 TNFSF activities enhancing immune cell activation

Markers of cancer cell and lymphocytes in inflammatory infiltration around a tumour as potential markers of immunomodulatory treatment response. Markers.

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 6 Combination therapy for HCC

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Approaches to targeting inhibitory immune receptors

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Figure 2 Altered innate immune functions after sepsis

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Influence of fucosylation on IgG effector functions

Figure 2 Emerging models of antibody-mediated rejection (ABMR) and

Figure 3 Effect of sialylated glycoforms on IgG activity

Figure 3 Multi-hit model for autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 The role of CTLA4 and PD1 in T cell activation

Targets for immunotherapy of liver cancer

Figure 2 Approaches to improve CAR-T-cell therapy

Figure 4 TNFSF inflammatory activities in tissue cells

Figure 2 Site of action of checkpoint inhibitors and agonists being

Mechanisms of immune escape in the tumor microenvironment.

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Endocrinol. doi: /nrendo

Johan Botling, MD, PhD, Martin Sandelin, MD, PhD

Figure 2 The hypoxia-induced proinflammatory

Nat. Rev. Rheumatol. doi: /nrrheum

TIGIT and CD226: Tipping the Balance between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit Kristen E. Pauken,

Figure 1 Mechanisms of action of immunotherapy modalities

Nat. Rev. Urol. doi: /nrurol

Figure 2 Cellular contributions to the development of SLE

Figure 3 Underlying mechanisms of TREG cells in atherosclerosis

Figure 1 The role of macrophages in RA

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Releasing the Brakes on Cancer Immunotherapy

Nat. Rev. Rheumatol. doi: /nrrheum

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Figure 2 Involvement of plasmacytoid dendritic cells

Presentation transcript:

Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2016.131 Figure 2 Expression of inhibitory immune receptors on different immune cells Figure 2 | Expression of inhibitory immune receptors on different immune cells. Various inhibitory receptors are expressed by T cells (part a), B cells (part b), dendritic cells (DCs) and macrophages (part c) and neutrophils (part d). The figure shows the ligands for inhibitory receptors discussed in this Review and, where relevant, shows the co-stimulatory receptors that share these ligands. BDCA2, blood-derived dendritic cell antigen 2; CD200R1, CD200 receptor 1; CTLA4, cytotoxic T-lymphocyte-associated antigen 4; FcγRIIB, low-affinity immunoglobulin-γ Fc region receptor IIb; PECAM1, platelet endothelial cell adhesion molecule; PILRα, paired immunoglobulin-like type 2 receptor-α; PD1, programmed cell death protein 1; PDL1, PD1 ligand 1; PVR, poliovirus receptor; TIGIT, T-cell immunoreceptor with immunoglobulin and ITIM domains; VISTA, V-type immunoglobulin domain suppressor of T cell activation; VISTA-R, VISTA receptor (unknown); VSTM1, V-set and transmembrane domain-containing protein 1; VSTM1-L, VSTM1 ligand (unknown). van der Vlist, M. et al. (2016) Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2016.131